Prevalence of potential drug-drug interactions in ambulatory patients with statin therapy;Prävalenz potentieller arzneimittelinteraktionen bei ambulanten patienten unter statin-therapie

Praxis

Volumn 95, Issue 5, 2006, Pages 139-146

  Ratz Bravo A E ^a   Tchambaz, L ^a   Krahenbuhl Melcher A ^b   Hess, L ^c   Schlienger, R G ^a   Krahenbuhl S ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Regionalspital Emmental   (Switzerland)

^c Brunner and Hess Software AG   (Switzerland)

Author keywords

Drug interactions; Dyslipidaemia; Outpatients; Prevalence; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; AMBULATORY CARE; ARTICLE; CLINICAL TRIAL; COMORBIDITY; DRUG COMBINATION; DRUG INTERACTION; DRUG SURVEILLANCE PROGRAM; EUROPE; FACTUAL DATABASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AMBULATORY CARE; COMORBIDITY; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED;

EID: 32044459933     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.95.5.139     Document Type: Article

References (41)

1. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9: 51-9. (Pubitemid 23222527)
2. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652-8. (Pubitemid 37430270)
3. Grymonpre RE, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 1988; 36: 1092-8. (Pubitemid 19005050)
4. Cadieux RJ. Drug interactions in the elderly. How multiple drug use increases risk exponentially. Postgrad Med 1989; 86: 179-86. (Pubitemid 20030817)
5. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001; 15 : 897-918. (Pubitemid 34110600)
6. Martin-Facklam M, Drewe J, Haefeli WE. Arzneimittel-Interaktionen am Cytochrom- P450-System. Dtsch Med Wochenschr 2000; 125: 63-7.
7. Drewe J, Krähenbühl S. Klinische Pharmakologie: Proteine für den Transport von Arzneistoffen. Schweiz Med Wochenschr 2000; 130: 727-31. (Pubitemid 30339931)
8. Federman DG, Hussain F,Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 2001; 94: 1023-6.
9. Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. Am J Med 2000; 108: 351-2. (Pubitemid 30110471)
10. Heerey A, Barry M, Ryan M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000; 169: 176-9. (Pubitemid 32149590)
11. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000; 23: 197-213.
12. Horsmans Y. Differential metabolism of statins: importance in drug-drug interactions. Eur Heart J Supplements 1999; 1 (Suppl T): T7-T12.
13. Rogers JF, Nafziger AN, Bertino JS, Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 746-50. (Pubitemid 36044701)
14. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-71.
15. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111: 390-400. (Pubitemid 32913673)
16. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 357-64. (Pubitemid 33787186)
17. Klasco RK, Moore L, editors. Drug-Reax® System. Greenwood Village, CO: Micromedex; 1974 - 2002.
18. Tatro DS, editor. Drug Interaction Facts(tm). St. Louis: Facts and Comparisons; 2003.
19. Stockley IH, editor. Drug Interactions. 51 ed. London: The Pharmaceutical Press; 1999.
20. ICH SC. ICH Harmonised tripartitude guideline. Clinical safety data management: definitions and standards for expedited reporting E2A. In. Geneva; 1994. p. 1-10.
21. Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Prevalence of potentially severe drug-drug interactions in ambulatory dyslipidemic patients receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28: 263-75. (Pubitemid 40364892)
22. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6 65-70.
23. Martin J, Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Saf 2003; 26: 13-21. (Pubitemid 36092272)
24. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-70. (Pubitemid 34713089)
25. Hsiang B, Zhu Y,Wang Z,Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl- CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161-8.
26. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538-44. (Pubitemid 37249124)
27. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transportermediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304: 610-6. (Pubitemid 36152336)
28. Boyd RA, Stern RH, Stewart BH,Wu X, Reyner EL, Zegarac EA, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-8.
29. Omar MA,Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-95. (Pubitemid 34126824)
30. Herman RJ. Drug interactions and the statins.CMAJ 1999; 161: 1281-6.
31. Yamreudeewong W, DeBisschop M, Martin L, Lower D. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003; 26: 421-38. (Pubitemid 36560714)
32. Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51: 461-70. (Pubitemid 32852984)
33. Swift CG. The clinical pharmacology of ageing. Br J Clin Pharmacol 2003; 56: 249-53. (Pubitemid 37059652)
34. Köhler GI, Bode-Boger SM, Busse R, Hoopmann M,Welte T, Boger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38: 504-13.
35. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58: 773-8. (Pubitemid 36399235)
36. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17. (Pubitemid 29407370)
37. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.BMJ 2003; 327: 1141-2. (Pubitemid 37421809)
38. Pennell DJ, Nunan TO, O'Doherty MJ, Croft DN. Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol. Lancet 1984; 1: 463. (Pubitemid 14193088)
39. Samanta A, Burden AC. Fever,myalgia, and arthralgia in a patient on captopril and allopurinol. Lancet 1984; 1: 679. (Pubitemid 14169493)
40. Ahmad S. Allopurinol and enalapril. Drug induced anaphylactic coronary spasm and acute myocardial infarction. Chest 1995; 108: 586.
41. Egger T, Dormann H, Ahne G, Runge U, Neubert A, Criegee-Rieck M, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003;20: 769-76. (Pubitemid 36995253)